Janssen’s SGLT-2 Diabetes Drug Gets Tentative Thumbs Up From FDA Panel

Washington Drug Letter
A panel of FDA advisers voted to recommend approval of Janssen Pharmaceuticals’ Type 2 diabetes drug canagliflozin, saying the drug’s apparent cardiovascular risks (CV) were likely a product of incomplete safety data and could be allayed by long-term postmarket studies.

To View This Article:


Buy This Article Now

Add this article to your cart for $25.00